Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of lerodalcibep in Chinese adults with hypercholesterolemia
CTR20242095Phase 3Completed
- Sponsor
- LIB Therapeutics
- Start
- Nov 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of lerodalcibep in hypercholesterolemia, familial hypercholesterolemia (FH), sponsored by LIB Therapeutics. Started Nov 2024; status: completed.
02
Drugs
lerodalcibep
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on CTR20242095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242095.